This study adds to the limited literature on type 2 diabetes mellitus and GLP-1 receptor agonists by providing new evidence on the real-world usage of exenatide (twice daily and once weekly), dulaglutide, liraglutide and lixisenatide in Italy. Here, GLP1R is linked to type 2 diabetes mellitus.